PL3833665T3 - Diazabicykloktanony jako inhibitory beta-laktamaz serynowych - Google Patents

Diazabicykloktanony jako inhibitory beta-laktamaz serynowych

Info

Publication number
PL3833665T3
PL3833665T3 PL19755850.5T PL19755850T PL3833665T3 PL 3833665 T3 PL3833665 T3 PL 3833665T3 PL 19755850 T PL19755850 T PL 19755850T PL 3833665 T3 PL3833665 T3 PL 3833665T3
Authority
PL
Poland
Prior art keywords
diazabicycloctanones
lactamase inhibitors
serine beta
serine
beta
Prior art date
Application number
PL19755850.5T
Other languages
English (en)
Inventor
Simon Leiris
David Thomas Davies
Original Assignee
Antabio Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18290093.6A external-priority patent/EP3608318A1/en
Priority claimed from EP18213635.8A external-priority patent/EP3670512A1/en
Application filed by Antabio Sas filed Critical Antabio Sas
Publication of PL3833665T3 publication Critical patent/PL3833665T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL19755850.5T 2018-08-09 2019-08-08 Diazabicykloktanony jako inhibitory beta-laktamaz serynowych PL3833665T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18290093.6A EP3608318A1 (en) 2018-08-09 2018-08-09 Diaazabicyclooctanone derivatives as antibacterials
EP18213635.8A EP3670512A1 (en) 2018-12-18 2018-12-18 Diazabicyclooctanones as inhibitors of serine beta-lactamases
PCT/EP2019/071370 WO2020030761A1 (en) 2018-08-09 2019-08-08 Diazabicyclooctanones as inhibitors of serine beta-lactamases

Publications (1)

Publication Number Publication Date
PL3833665T3 true PL3833665T3 (pl) 2023-12-27

Family

ID=67667824

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19755850.5T PL3833665T3 (pl) 2018-08-09 2019-08-08 Diazabicykloktanony jako inhibitory beta-laktamaz serynowych

Country Status (24)

Country Link
US (1) US12378244B2 (pl)
EP (2) EP3833665B1 (pl)
JP (1) JP7429988B2 (pl)
KR (1) KR102790878B1 (pl)
CN (2) CN111954671B (pl)
AU (1) AU2019318115B2 (pl)
BR (1) BR112021002311A2 (pl)
CA (1) CA3110111A1 (pl)
DK (1) DK3833665T3 (pl)
ES (1) ES2960952T3 (pl)
FI (1) FI3833665T3 (pl)
HR (1) HRP20231228T1 (pl)
HU (1) HUE063324T2 (pl)
IL (1) IL280770B2 (pl)
LT (1) LT3833665T (pl)
MX (1) MX2021001564A (pl)
PL (1) PL3833665T3 (pl)
RS (1) RS64679B1 (pl)
SG (1) SG11202101255UA (pl)
SI (1) SI3833665T1 (pl)
SM (1) SMT202300354T1 (pl)
TW (1) TWI764030B (pl)
WO (1) WO2020030761A1 (pl)
ZA (1) ZA202100906B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111943950B (zh) * 2020-09-10 2022-03-29 山东安信制药有限公司 一种瑞来巴坦的制备方法
EP4146651B1 (en) 2021-05-07 2026-03-04 Ningxia Academy of Agriculture and Forestry Sciences Sulfonylamidine substituted compounds and their use as beta-lactamase inhibitors
CN115448920B (zh) * 2022-10-14 2025-01-03 广州楷石医药有限公司 一种β-内酰胺酶抑制剂及其应用
GB202306833D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
GB202306826D0 (en) 2023-05-09 2023-06-21 Adjutec Pharma As Therapy
CN117700415B (zh) * 2024-02-06 2024-04-30 成都四面体药物研究有限公司 含脲双环化合物、其用途、其制备的药物、其联合用药物及其复方制剂
WO2025215253A1 (en) * 2024-04-12 2025-10-16 Antabio Sas Dosing regimen comprising (2r,5r)-2-fluoro-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulphate and a beta-lactam antibiotic

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0180798B1 (ko) 1993-11-06 1999-03-20 고바야시 요시오 결정성 페니실린 유도체, 그의 제법 및 용도
US6979735B1 (en) 1999-04-01 2005-12-27 Dsm N.V. Agglomerates by crystallization
DK1206261T3 (da) 1999-08-16 2006-07-03 Revaax Pharmaceuticals Llc Farmaceutiske præparater, der omfatter clavuansyre eller derivater deraf, til behandlingen af adfærdsmæssige sygdomme
US20030148324A1 (en) 2001-02-02 2003-08-07 Edouard Bingen Polynucleotides which are of nature B2/D+ A- and which are isolated from E. coli, and biological uses of these polynucleotides and of their polypeptides
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
SE0102058D0 (sv) 2001-06-08 2001-06-08 Astrazeneca Ab New Salts II
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
DE10218328A1 (de) 2002-03-05 2003-09-25 Humboldt Uni Zu Berlin Medizin Mittel zur präventiven Therapie nach akutem Schlaganfall
EP1342784A1 (en) 2002-03-06 2003-09-10 Mutabilis S.A. ExPEC-specific proteins, genes encoding them and uses thereof
JP2005519623A (ja) 2002-03-13 2005-07-07 クレイトン ユニヴァーシティー 抗生物質不活性化酵素を検出するための装置及び方法
FR2842210B1 (fr) 2002-07-09 2012-12-14 Mutabilis Determinants de pathogenicite utilisables comme cibles pour l'elaboration de moyens de prevention et de controle d'infections bacteriennes et/ou de la dissemination systemique
US6928313B2 (en) 2003-01-27 2005-08-09 Cardiac Pacemakers, Inc. System and method for accessing the coronary sinus to facilitate insertion of pacing leads
WO2005077019A2 (en) 2004-02-05 2005-08-25 The General Hospital Corporation Protease inhibitors for treatment of wrinkles
EP1580195A1 (en) 2004-03-26 2005-09-28 Mutabilis SA Compositions of polypeptides specific to pathogenic ExPEC E. coli strains and their use as vaccines and in immunotherapy
CN101060846A (zh) 2004-12-02 2007-10-24 维纳斯药业有限公司 采用可用于注射的β－内酰胺酶抑制剂防止β－内酰胺酶介导抗生素抗性的成分
EP1669365A1 (en) 2004-12-03 2006-06-14 Mutabilis SA Method for preparing enzymatic substrate analogs as inhibitors of bacterial heptosyl-transferases
CA2591157C (en) 2004-12-17 2012-06-12 Venus Remedies Limited Antibiotic combinations for providing total solution to the treatment of infections
EP1981545A2 (en) 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
US20070202050A1 (en) 2006-02-09 2007-08-30 Julianne Berry Pharmaceutical Formulations
EP1845087A1 (en) 2006-04-14 2007-10-17 Mutabilis SA Hydroxyphenyl derivatives and biological applications thereof
EP2029623A2 (en) 2006-06-19 2009-03-04 Mutabilis SA Identification of genes implicated in the virulence of streptococcus agalactiae
EP2104671A2 (en) 2006-09-25 2009-09-30 Mutabilis SA Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
EP1972629A1 (en) 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
CN101918407B (zh) * 2008-01-18 2014-02-26 默沙东公司 β-内酰胺酶抑制剂
EP2141164A1 (en) 2008-07-01 2010-01-06 Mutabilis New 1,2,4-triazine derivatives and biological applications thereof
WO2010043893A1 (en) 2008-10-14 2010-04-22 Astrazeneca Ab Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
JP5651186B2 (ja) 2009-10-30 2015-01-07 バイオジェニック イノベーションズ， リミテッド ライアビリティ カンパニー 薬剤耐性微生物を処置するためのメチルスルホニルメタン（ｍｓｍ）
WO2012030647A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
WO2012073214A2 (en) 2010-12-01 2012-06-07 Laboratoire Biodim New heptose derivatives and biological applications thereof
SG191320A1 (en) 2010-12-22 2013-07-31 Meiji Seika Pharma Co Ltd Optically-active diazabicyclooctane derivative and method for manufacturing same
TWI565706B (zh) 2011-06-17 2017-01-11 阿斯特捷利康公司 用於製備包括反－７－酮基－６－（磺酸氧基）－１，６－二氮雜雙環［３，２，１］辛烷－２－甲醯胺之雜環化合物及其鹽類之方法
JP5808860B2 (ja) 2011-07-26 2015-11-10 ウォックハート リミテッド スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物
RU2570423C2 (ru) * 2011-08-30 2015-12-10 Вокхардт Лимитед Производные 1,6-диазабицикло[3.2.1]октан-7-она и их применение при лечении бактериальных инфекций
ES2640520T3 (es) 2011-09-13 2017-11-03 Wockhardt Limited Compuestos que contienen nitrógeno y su uso
US20130108670A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating full thickness burn injuries
US20130108683A1 (en) 2011-10-25 2013-05-02 Biomimetic Therapeutics, Inc. Compositions and methods for treating partial and full thickness wounds and injuries
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
TW201343646A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc 異□唑β－內醯胺酶抑制劑
SG11201406123TA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
WO2013180197A1 (ja) 2012-05-30 2013-12-05 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規β－ラクタマーゼ阻害剤とその製造法
WO2014033560A1 (en) 2012-08-25 2014-03-06 Wockhardt Limited 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
WO2014052799A1 (en) 2012-09-27 2014-04-03 Cubist Pharmaceuticals, Inc. Tazobactam arginine antibiotic compositions
EP2725029A1 (en) 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
UA111925C2 (uk) * 2012-12-11 2016-06-24 Федора Фармасьютікалз Інк. БІЦИКЛІЧНІ СПОЛУКИ ТА ЇХ ВИКОРИСТАННЯ ЯК АНТИБАКТЕРІАЛЬНИХ АГЕНТІВ ТА ІНГІБІТОРІВ β-ЛАКТАМАЗИ
CN104884092A (zh) 2013-01-14 2015-09-02 沃克哈特有限公司 用于治疗细菌感染的组合物和方法
US8889671B2 (en) 2013-01-23 2014-11-18 Astrazeneca Ab Compounds and methods for treating bacterial infections
CN110302203A (zh) 2013-02-06 2019-10-08 辉瑞抗感染公司 用于治疗医院性肺炎的组合疗法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
ES2495666B1 (es) 2013-03-15 2015-08-10 Laboratoris Sanifit, S.L. Uso de derivados con enlaces c-o-p en pacientes con fallo renal
US9364490B2 (en) 2013-03-15 2016-06-14 Laboratoris Sanifit, S.L. Use of derivatives containing C—O—P bonds in patients with kidney failure
GB201310542D0 (en) 2013-06-13 2013-07-31 Antabio Sas Compounds
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
CN106132411A (zh) 2013-10-22 2016-11-16 沃克哈特有限公司 包含抗菌剂的药物组合物
JP2017502970A (ja) 2014-01-21 2017-01-26 ウォックハート リミテッド 窒素含有化合物及びその使用
CN105980385B (zh) 2014-02-03 2018-01-09 沃克哈特有限公司 制备(2s,5r)‑1,6‑二氮杂‑二环[3.2.1]辛烷‑2‑腈‑7‑氧代‑6‑(磺氧基)‑单钠盐的方法
WO2015125031A1 (en) 2014-02-20 2015-08-27 Wockhardt Limited Pharmaceutical combinations comprising antibacterial agents
EP2913330A1 (en) 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
KR20160126004A (ko) 2014-03-14 2016-11-01 욱크하르트 리미티드 항세균제를 포함하는 제약학적 조성물
WO2015148379A1 (en) 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
CN107980000A (zh) 2014-04-18 2018-05-01 沃克哈特有限公司 包含抗菌剂的药物组合物
WO2015159167A1 (en) 2014-04-18 2015-10-22 Wockhardt Limited Pharmaceutical compositions comprising antibacterial agents
EA033459B1 (ru) 2014-05-29 2019-10-31 Entasis Therapeutics Ltd Конденсированные спироциклические гетероароматические соединения для лечения бактериальных инфекций
US20150361108A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
DK3221313T3 (en) 2014-11-17 2019-04-08 Entasis Therapeutics Ltd COMBINATION THERAPY FOR TREATING INFECTIONS WITH RESISTANT BACTERIA
GB2533136A (en) 2014-12-11 2016-06-15 Antabio Sas Compounds
WO2016116788A1 (en) 2015-01-24 2016-07-28 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2016128867A1 (en) 2015-02-12 2016-08-18 Wockhardt Limited Azetidinone containing compounds and their use in treatment of bacterial infections
US10072006B2 (en) 2015-03-31 2018-09-11 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CA2980109A1 (en) 2015-03-31 2016-10-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
BR112017020935A2 (pt) 2015-04-03 2018-07-10 Mutabilis ?compostos, composição farmacêutica e conjunto?
CA2983674A1 (en) 2015-05-07 2016-11-10 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2017002083A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002089A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002087A1 (en) 2015-07-02 2017-01-05 Wockhardtlimited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
WO2017002086A1 (en) 2015-07-02 2017-01-05 Wockhardt Limited Nitrogen containing bicyclic compounds and their use in treatment of bacterial infections
CN106467705B (zh) 2015-08-17 2019-02-22 3M创新有限公司 防滑液、防滑件及其制备方法
WO2017037607A1 (en) 2015-09-01 2017-03-09 Wockhardt Limited (aminomethylidene)amino-substituted (2s,5r)-6-(sulfonyl)-7-oxo-1,6-diazabicyclo[3.2.1 ]octane-2-carboxamide derivatives with antibacterial activity
KR20180066264A (ko) 2015-12-10 2018-06-18 나에자-알지엠 파마슈티칼스 유엘씨 세펨 화합물, 그의 제조 및 용도
EP3184529A1 (en) 2015-12-23 2017-06-28 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US10040784B2 (en) 2016-03-11 2018-08-07 California Institute Of Technology Compositions and methods for acylating lactams
WO2017203266A1 (en) 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
CN109310682A (zh) 2016-06-17 2019-02-05 沃克哈特有限公司 抗菌组合物
KR102537340B1 (ko) 2016-09-16 2023-05-26 엔타시스 테라퓨틱스 리미티드 베타-락타마제 억제제 화합물
EP3300736B1 (en) 2016-09-30 2021-05-05 Mutabilis Composition comprising antibiotic compound and an heterocyclic compound and their use in preventing or treating bacterial infections
WO2018129008A1 (en) 2017-01-04 2018-07-12 Entasis Therapeutics Inc. Compounds and methods for treating bacterial infections
EP3357924A1 (en) 2017-02-06 2018-08-08 Mutabilis Novel heterocyclic compounds and their use in preventing or treating bacterial infections
TW201831482A (zh) 2017-02-06 2018-09-01 法商木塔比利斯公司 新穎雜環化合物及其預防或治療細菌感染之用途
MA48743A (fr) 2017-05-08 2020-04-08 Entasis Therapeutics Inc Composés et méthodes de traitement d'infections bactériennes
KR20200030584A (ko) * 2017-07-21 2020-03-20 앤타바이오 에스에이에스 화합물
CN107501265B (zh) * 2017-10-09 2019-05-28 台州职业技术学院 一种7-氧代-二氮杂二环[3,2,1]辛烷衍生化合物及其制备方法和应用
WO2019093450A1 (ja) * 2017-11-10 2019-05-16 塩野義製薬株式会社 ジアザビシクロオクタン誘導体
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
EP3604309A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3604315A1 (en) 2018-07-30 2020-02-05 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
US11905286B2 (en) * 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases

Also Published As

Publication number Publication date
IL280770B2 (en) 2024-05-01
EP4272831A3 (en) 2024-02-21
SG11202101255UA (en) 2021-03-30
MX2021001564A (es) 2021-05-12
SMT202300354T1 (it) 2023-11-13
WO2020030761A1 (en) 2020-02-13
US20240391919A1 (en) 2024-11-28
RS64679B1 (sr) 2023-11-30
TW202019929A (zh) 2020-06-01
CA3110111A1 (en) 2020-02-13
KR102790878B1 (ko) 2025-04-02
EP3833665B1 (en) 2023-07-19
IL280770A (en) 2021-04-29
EP4272831A2 (en) 2023-11-08
BR112021002311A2 (pt) 2021-05-04
SI3833665T1 (sl) 2023-12-29
ES2960952T3 (es) 2024-03-07
DK3833665T3 (da) 2023-10-09
IL280770B1 (en) 2024-01-01
KR20210055701A (ko) 2021-05-17
TWI764030B (zh) 2022-05-11
HUE063324T2 (hu) 2024-01-28
EP3833665A1 (en) 2021-06-16
AU2019318115B2 (en) 2024-04-18
ZA202100906B (en) 2023-07-26
US12378244B2 (en) 2025-08-05
FI3833665T3 (fi) 2023-10-09
JP2021534095A (ja) 2021-12-09
HRP20231228T1 (hr) 2024-01-19
AU2019318115A1 (en) 2021-03-11
CN117384155A (zh) 2024-01-12
LT3833665T (lt) 2023-11-10
CN111954671A (zh) 2020-11-17
JP7429988B2 (ja) 2024-02-09
CN111954671B (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
EP4007752C0 (en) Kif18a inhibitors
MA54550A (fr) Inhibiteurs de kif18a
EP4007753C0 (en) Kif18a inhibitors
EP3898616C0 (en) HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
EP3898592C0 (en) HETEROARYL AMIDES USEFUL AS KIF18A INHIBITORS
EP4007756C0 (en) KIF18A INHIBITORS
PL3697785T3 (pl) Związki imidazopirydynowe jako inhibitory pad
HUE060282T2 (hu) Béta-laktamáz gátló vegyületek
EP3801503A4 (en) INHIBITORS OF SARM1
PL3833665T3 (pl) Diazabicykloktanony jako inhibitory beta-laktamaz serynowych
PL3468966T3 (pl) Inhibitory interakcji menina-mll
PL3224256T3 (pl) Związki n-((het)arylometylo-heteroarylo-karboksyamidowe jako inhibitory kalikreiny osoczowej
PL3154989T3 (pl) Inhibitory beta-laktamaz
PL4051688T3 (pl) Inhibitory cd73
MA52813A (fr) Inhibiteurs de sarm1
CL2021000426A1 (es) Inhibidores de la interacción proteína-proteína keap1-nrf2.
EP3817736A4 (en) PIKFYVE INHIBITORS
DK3261639T3 (da) Substituerede pyrazolforbindelser som serinproteaseinhibitorer
EP3790871C0 (en) FURIN INHIBITORS
MA52809A (fr) Inhibiteurs de sarm1
EP3980011C0 (en) SARM1 HIBITORS
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
PL3552017T3 (pl) Związki użyteczne jako inhibitory RIPK1
EP3768272A4 (en) JAK HEMMER